Type-specific human papillomavirus oncogene messenger RNA levels correlate with the severity of cervical neoplasia

International Journal of Cancer

Volumn 127, Issue 3, 2010, Pages 622-632

  Ho, Chih Ming ^a,b,c   Lee, Bor Heng ^d   Chang, Shwu Fen ^e   Chien, Tsai Yen ^a   Huang, Shih Hung ^a   Yan, Chiu Cho ^d   Cheng, Wen Fang ^f  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d King Car Food Industrial Co Ltd   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cervical intraepithelial neoplasm; Human papillomavirus; mRNA; Viral load

Indexed keywords

MESSENGER RNA; PROTEIN E6; TUMOR MARKER; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOLOGY; DISEASE SEVERITY; DNA HYBRIDIZATION; FEMALE; GENE AMPLIFICATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; MAJOR CLINICAL STUDY; MIXED INFECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; UTERINE CERVIX CARCINOMA IN SITU; VALIDATION PROCESS; VIRUS LOAD; VIRUS ONCOGENE; WART VIRUS;

ALPHAPAPILLOMAVIRUS; BASE SEQUENCE; CROSS-SECTIONAL STUDIES; DNA PRIMERS; FEMALE; HUMANS; NUCLEIC ACID HYBRIDIZATION; ONCOGENES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 77954433214     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25078     Document Type: Article

References (37)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
2. Zur Hausen H. Papillomavirus causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-8. (Pubitemid 30365529)
3. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
4. Von Knebel Doeberitz M, Rittmuller C, Aengeneyndt F, Jansen-Durr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol 1994;68:2811-21. (Pubitemid 24129728)
5. Munoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, and the International Agency for Research on Cancer Multi-center Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348: 518-27.
6. Castle PE, Solomon D, Schiffman M, Wheeler CM for the ALTS Group. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005;97: 1066-71.
7. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74.
8. Liaw KL, Hsing AW, Chen CJ, Schiffman MH, Zhang TY, Hsieh CY, Greer CE, You SL, Huang TW, Wu TC. Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int J Cancer 1995;62:565-71.
9. Huang S, Afonina I, Miller BA, Bechmann M. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese Women. Int J Cancer 1997;70: 408-11.
10. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. Integrated human papillomavirus type 52 and 58 is infrequently found in cervical cancer and high viral loads predict risk of cervical cancer. Gynecol Oncol 2006;10:254-60.
11. Ho CM, Cheng WF, Chu TY, Chen CA, Chuang MH, Chang SF, Hsieh CY. Human papillomaviral load changes in low-grade squamous intraepithelial lesions of the uterine cervix. Br J Cancer 2006;95:1384-9.
12. Lai CH, Huang HJ, Hsueh S, Chao A, Lin CT, Huang SL, Chao FY, Qiu JT, Hong JH, Chou HH, Chang TC, Chang CJ. Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer 2007;120:1999-2006.
13. Chan PK, Li WH, Chan MY, Ma WL, Cheung JL, Cheng AF. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol 1999;59: 232-8.
14. Bae JH, Lee SJ, Kim CJ, Hur SY, Park YG, Lee WC, Kim YT, Ng TL, Bock HL, Park JS. Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. J Microbiol Biotechnol 2008;18: 788-94.
15. Tay SK, Ngan HY, Chu TY, Cheung AN, Tay EH. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong. Singapore and Taiwan. Vaccine 2008;26S:M60-70.
16. Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, Skomedal H. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol 2006;44: 1310-7.
17. Snijders PJF, Hogewoning CJA, Hesselink AT, Berkhof J, Voorhorst FJ, Bleeker MC, Meijer CJ. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer 2006;119:1102-7.
18. Molden T, Nygård JF, Kraus I, Karlsen F, Nygård M, Skare GB, Skomedal H, Thoresen SO, Hagmar B. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005;114:973-6.
19. Schneider-Maunoury S, Croissant O, Orth G. Integration of human papillomavirus type 16 DNA sequences: a possible early event in the progression of genital tumors. J Virol 1987;61:3295-8. (Pubitemid 17137683)
20. Ylitalo N, Sørensen P, Josefsson AM, Magnusson PK, Andersen PK, Pontén J, Adami HO, Gyllensten UB, Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2194-98.
21. Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F, Hagmar B. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer 2004;90:1407-13. (Pubitemid 38586270)
22. de Boer MA, Jordanova ES, Kenter GG, Peters AA, Corver WE, Trimbos JB, Fleuren GJ. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res 2007;13:132-8.
23. Scheurer ME, Tortolero-Luna G, Guillaud M, Follen M, Chen Z, Dillon LM, Adler-Storthz K. Correlation of human papillomavirus type 16 and human papillomavirus type 18 E7 messenger RNA levels with degree of cervical dysplasia. Cancer Epi Biomarker Prevent 2005;14: 1948-52.
24. Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel Doeberitz M. DNA aneuploidy and integration of human papillomavirus type 16 E6/E7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res 2006;10:3059-63.
25. Huang HJ, Huang SL, Lin CY, Chao FY, Chen MY, Chang TC, Hsueh S, Hsu KH, Lai CH. Human papillomavirus genotyping by a polymerase chain reaction-based gene chip method in cervical carcinoma treated with neo-adjuvant chemotherapy plus radical surgery. Int J Gynecol Cancer 2004; 14:639-49.
26. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 2002;94:2199-210.
27. Huang LW, Chao SL, Kwang JL. Human papillomavirus-31-related types predict better survival in cervical carcinoma. Cancer 2004;100:327-34.
28. Vinokurova S, Wentzensen N, Krus I, Klaes R, Driesch C, Melsheimer P, Kisseljov F, Dürst M, Schneider A, von Knebel Doeberitz M. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008;68:307-13.
29. Xi LF, Kiviat NB, Galloway DA, Zhou XH, Ho J, Koutosky LA. Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J Infect Dis 2008;198: 324-31.
30. Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Garcia S, Campo E, Pahisa J, Ordi J. High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing. Am J Obstet Gynecol 2007;197:359-65.
31. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Pontén J, Adami HO, Gyllensten UB, Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2194-8. (Pubitemid 30394326)
32. Joseffson AM, Magnusson PKE, Ylitalo N, Sørensen P, Qwarforth-Tubbin P, Andersen PK, Melbye M, Adami HO, Gyllensten UB. Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355:2189-93. (Pubitemid 30394325)
33. Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005;92: 891-4.
34. Cheung JK, Lo KWK, Cheung TH, Tang JW, Chan PS. Viral load. E2 gene disruption status, and lineage of human papillomavirus type 16 infection in cervical neoplasia. J Infect Dis 2006;194:1706-12.
35. Castle PE, Dockter J, Giachetti C, Francisco AR, McCormick MK, Mitchell AL. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical pre-cancer and cancer. Clin Cancer Res 2007;13:2599-605.
36. Liu SS, Tsang PC, Chang KY, Cheung AN, Chan KK, Leung RC, Ngan HY. Distribution of six oncogenic types of human papillomavirus and type 16 integration analysis in Chinese women with cervical precancerous lesions and carcinomas. Tumor Biol 2008;29: 105-13.
37. Chen CA, Liu CY, Chou HH, Ho CM, Twu NF, Kan YY, Chuang MH, Chu TY, Hsieh CY and the Taiwan Cooperative Oncologic Group (TCOG) Study. The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions. Int J Gynecol Cancer 2006;16:1801-8.